Fresenius Se & Co. Kgaa · XETR:FRE
Fresenius Se & Co. Kgaa — Investor Presentation (March 2015)
19 slides from Fresenius Se & Co. Kgaa's investor presentation, March 2015
Slide 1: A Leading Global Health Care Group
A Leading Global Health Care Group For detailed financial information please see our annual/quarterly reports and/or conference call materials on our website. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY
Slide 2: Fresenius At a Glance
Fresenius At a Glance A Global Leader in Health Care Products and Services - 2017 Target: sales ~€30 bn, net income ~€1.5 bn - Strong and well-diversified portfolio - Global presence in approx. 100 countries - Long-term opportunities in growing markets - Attractive total shareholder return: 10-year
Slide 3: Strong and Balanced Health Care Portfolio
Strong and Balanced Health Care Portfolio Ownership: 31% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis products and Hospital supplies Hospital operations Hospital projects services and services 2014 Group Net Income Contribution 22% 43% 37% 3% Corporate: -5% General Presentation, Fresenius
Slide 4: Evolving Industry Dynamics
Evolving Industry Dynamics Aging population and higher incidence of chronic diseases World population age 60+ will more than double by 2050 to >2 bn (OECD) Increasing health care spending in emerging markets Increasing health care coverage and per capita spending (e.g. India: US$157, China: US$480,
Slide 5: Well Positioned for Future Growth
Well Positioned for Future Growth Global R&D / Technology Emerging markets Services infrastructure Expertise presence − Global reach and scale − R&D and production − €3.7 bn sales in − Treating +285,000 technology are key emerging markets in dialysis patients; − +215,000 employees for long-term grow
Slide 6: Fresenius Medical Care: Global Market Leader in Dialysis
Fresenius Medical Care: Global Market Leader in Dialysis - Provide highest standard of patient care Industry Dynamics - High quality dialysis products & services - Complete therapy offerings Expected global patient growth: ~6% p.a. - Vertical integration 2020e: ~3.8 million patients ~3.8 - Service p
Slide 7: Fresenius Kabi: A Worldwide Leading Hospital Supplier
Fresenius Kabi: A Worldwide Leading Hospital Supplier - Comprehensive product portfolio for critically 2014 Sales by Region and chronically ill patients: - IV Drugs 29% - Clinical Nutrition Emerging markets €1,513 m - Infusion Therapy 41% - Medical Devices / Transfusion Technology Europe €2,102 m -
Slide 8: Fresenius Helios: Leading Private Hospital Operator in Germany
Fresenius Helios: Leading Private Hospital Operator in Germany - Acute and post-acute care in 110 proprietary Majority of population has access to a hospitals1 HELIOS hospital within one hour‘s drive ~29,100 acute care - High-quality medical care (e.g., mortality rate beds for heart failure and pneu
Slide 9: Fresenius Vamed: Hospital Projects and Services
Fresenius Vamed: A Leading Global Specialist in Hospital Projects and Services - Specialized in project development building 2014 Sales hospital infrastructure and providing hospital services (technical services and operational management) 46% 54% Services Projects - Track record: €484 m €558 m - >7
Slide 10: Excellent Financial Performance Driven by Strong Organic Growth and Acquisitions
Excellent Financial Performance Driven by Strong Organic Growth and Acquisitions Sales (€ billion) EBIT margin (%) 23.2 CAGR 12% 19.3 20.3 15.7 15.9 16.4 15.1 15.0 16.0 14.5 14.2 14.2 14.0 13.6 12.3 13.4 10.8 11.4 12.3 7.3 7.9 11.6 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2004 2005 200
Slide 11: Consistent Cash Generation and Proven Track Record of Deleveraging
Fresenius Group: Consistent Cash Generation and Proven Track Record of Deleveraging CFFO margin FCF margin (before acquisitions & dividends) % % 14 10 13 12.6 7.7 12.0 8 7.4 12 11.4 11.0 11.4 6.3 11.1 6.3 10.3 5.7 5.6 5.7 11 6 5.4 9.9 9.8 4.5 10 8.7 4 2.7 9 8 2 2005 2006 2007 2008 2009 2010 2011 201
Slide 12: Dividend Development and Total Shareholder Return
Fresenius Group: Dividend Development and Total Shareholder Return 22nd consecutive dividend increase Total Return: Fresenius outperforms index € 1 0.44 2014: + 6% 0.42 0.37 Fresenius 0.32 share ~20% p.a. 0.29 0.25 0.23 0.22 0.19 0.16 0.15 DAX30 ~9% p.a. 0.02 '93 '04 '05 '06 '07 '08 '09 '10 '11 '12
Slide 13: 2015 Financial Outlook by Business Segment
Fresenius Group: 2015 Financial Outlook by Business Segment Fresenius Sales growth organic 3% – 5% Kabi EBIT growth constant currency 4% – 6% Sales growth organic 3% – 5% Fresenius Sales growth reported 6% – 9% Helios EBIT €630 – 650 m Fresenius Sales growth organic single digit % Vamed EBIT growth
Slide 14: 2015 Financial Outlook
Fresenius Group: 2015 Financial Outlook Revenue growth 7% ‒ 10% at constant currency Net income growth1 9% ‒ 12% at constant currency 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs (hospitals of Rhön-Klinikum AG ~€10 million before tax), before co
Slide 15: Confirming 2017 Target / Exceeding Target at Current FX Rates
Fresenius Group: Confirming 2017 Target / Exceeding Target at Current FX Rates ~€30 billion Sales; €1.4 to €1.5 billion Net Income Sales Net Income1 €bn €m CAGR 9-11% ~1,400-1,500 CAGR 9% ~30 3% 1,086 14% 1,051 23.2 20.3 2013 2014 2017 2013 2014 2017 General Presentation, Fresenius SE & Co. KGaA, In
Slide 16: Investment Highlights
Investment Highlights - Diversified revenue and earnings base with four strong business segments - Leading positions in non-cyclical markets with predictable growth - Industry-leading organic growth in all business segments - Strong earnings performance and cash flow generation - Attractive sharehol
Slide 17: More than 100 Years of Forward Looking Healthcare
Fresenius: More than 100 Years of Forward Looking Healthcare Oct. 1 - the day Introduction of IPO No. 1 in dialysis No. 1 in German No. 1 in it all began dialysis machines worldwide hospital operations Transfusion and dialyzers Technology worldwide 1912 1966 1986 1996 2005 2012 1994: 2006: 2014: Sal
Slide 18: Share Information
Share Information Share key facts Number of shares1 541,919,723 WKN / ISIN 578560 / DE0005785604 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de ADR key facts Ratio 4 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Ticker symbol FSNUY Exchange OTCQX International P
Slide 19: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Fresenius SE & Co. KGaA — Investor Presentation (March 2015) on 6ix